Perifolliculitis Capitis Abscedens Et Suffodiens Treatment With Tumor Necrosis Factor Inhibitors and Baricitinib: A Case Report and Literature Review

    March 2023 in “ Frontiers in medicine ”
    Yuanting Yu, Xiaojie Ding, Fei Guo … Xin Li
    Studysummary This case report presents the first successful treatment of perifolliculitis capitis abscedens et suffodiens using a regimen of adalimumab and baricitinib, resulting in almost complete healing after nine months.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study Journal of The American Academy of Dermatology · 2021
    2. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017
    3. Dissecting Cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): A Comprehensive Review Focusing on New Treatments and Findings of the Last Decade with Commentary Comparing the Therapies and Causes of Dissecting Cellulitis to Hidradenitis Suppurativa Dermatology Online Journal · 2014